Hematology/Oncology

Top Story

FDA expands approval of Stivarga to include liver cancer

April 27, 2017

The FDA expanded the approval of regorafenib to include the treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib.

Regorafenib (Stivarga, Bayer) — a kinase inhibitor that works by blocking several enzymes that promote cancer growth — is the first FDA–approved treatment for liver cancer in nearly a decade.

Meeting News

Contralateral breast cancer uncommon among women with ductal carcinoma in situ

April 27, 2017
Fewer than 6% of women with ductal carcinoma in situ developed contralateral breast cancer within 10 years, according to study results presented at the American Society…
In the Journals Plus

Incidence, prevalence of neuroendocrine tumors on the rise

April 27, 2017
Incidence and prevalence of neuroendocrine tumors are steadily rising, possibly due to better detection of early-stage disease and stage migration, according to a…
FDA News

FDA grants breakthrough therapy designation to lorlatinib for ALK–positive NSCLC

April 27, 2017
The FDA granted breakthrough therapy designation to lorlatinib for the treatment of patients with anaplastic lymphoma kinase–positive metastatic non–small…
In the Journals Plus

Clofarabine shows promise as alternative chemotherapy for younger patients with AML

April 27, 2017
Clofarabine-based combination therapy may serve as a new option for chemotherapy among younger patients with acute myeloid leukemia in their first remission, study data
More News Headlines »
CME CNE CPE

Individualized Prophylaxis in Hemophilia

Support for this activity has been made possible through an educational grant from Bayer HealthCare Pharmaceuticals

This program will provide education for hematologists, nurses, pharmacists, and other healthcare providers involved in…
More »
Video
Meeting News

VIDEO: Speaker compares single-agent vs. combination immunotherapy for melanoma

April 9, 2017
More »
Featured
American Association for Cancer Research Annual Meeting

American Association for Cancer Research Annual Meeting

CME

What's Hot in Melanoma? Highlights from the HemOnc Today Melanoma and Cutaneous Malignancies 2017 Meeting

This activity is supported by an educational grant from Merck & Co, Inc.

The development and integration of targeted therapies, as well as immunotherapies, into clinical strategies for the…
More »
Current Issues
View the Current Issue
HemOnc Today
Advertisement
Advertisement